about
Exacerbation of isoniazid induced peripheral neuropathy by pyridoxinePolymorphic acetylation of sulphamethazine in a Zimbabwe population.Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distributionAcetylator phenotypes in Papua New Guinea.N-acetylation phenotyping using dapsone in a Jordanian populationAcetylator phenotype and adverse effects of sulphasalazine in healthy subjects.Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.Comparative biology of test species.Tuberculosis: who should prescribe?The use of anti-tuberculosis therapy for latent TB infectionClinically relevant genetic variations in drug metabolizing enzymes.N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.ENZYMES AND DRUG SENSITIVITY. ACETYLATION POLYMORPHISMSDiathesis and disease. The Osler oration, 1963Role of pharmacogenomics in the treatment of tuberculosis: a reviewA second international co-operative investigation into thioacetazone side-effects. 1. The influence of a vitamin and antihistamine supplementEffect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid.Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis.The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis: 1. An assessment of two vitamin B preparations and glutamic acidTHE PREVENTION AND TREATMENT OF ISONIAZID TOXICITY IN THE THERAPY OF PULMONARY TUBERCULOSIS. 2. AN ASSESSMENT OF THE PROPHYLACTIC EFFECT OF PYRIDOXINE IN LOW DOSAGEProgress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rateAnti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.The scope of the controlled clinical trial, illustrated by studies of pulmonary tuberculosis.Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase.The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PASRate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PASSimultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.MULTIPLE DEFICIENCY STATE ASSOCIATED WITH ISONIAZID THERAPY.REALISTIC CHEMOTHERAPEUTIC POLICIES FOR TUBERCULOSIS IN THE DEVELOPING COUNTRIES.Antinuclear antibodies during procainamide treatment and drug acetylation.Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
P2860
Q28330601-D1AFC188-66A2-4F88-8B35-AE7F25C66184Q33592378-B638BA6B-00F5-4F2B-AFE9-0860AED74B50Q33668919-35F0178D-7A1D-4484-B045-1AB0B736A311Q33670130-82EA1BF3-DBB1-48A8-99CD-F6F139FBEDD9Q34358640-F75AD372-6247-4937-B58D-8D59E7389974Q34474823-99121526-A218-4B28-A7E3-42E04BAD6E69Q34496962-DFC133BE-A95F-4EBE-AEA0-627678FA980DQ34660522-23786099-4793-453A-AAC6-1AD3B16E5113Q34748538-00372A93-F92D-4C29-9933-4400501AFAE8Q35026573-B8FF6876-2456-4B1A-BA64-18867BF5D336Q35032378-831ACCE5-737D-421F-9474-74C225353CDCQ35133059-C64FE624-15D6-4694-8E1D-4B4015483756Q35853450-F937F1AC-9AE9-4885-A6CF-CEE38A580C0EQ35896448-3B8AC33D-FA77-4892-BBD5-AED8830703DAQ36441540-3EBBE30C-8BEF-4C3B-AB3F-C6AAFE5B7F9FQ36719962-5EBF837D-1E89-4AC8-B1FB-5BA9995D76F0Q36779479-7CE37E63-EB1D-463D-8E01-1870A4FDAA64Q36786016-F36376AF-9027-4306-86F3-9F3F29B1D647Q36911766-D7F5D8A5-F8A0-45A2-9C7E-E5825DD2D543Q36912304-2A64B1A6-60EA-4E5F-9876-F4E837A31957Q36913497-30677003-40BE-4C28-837A-F8870E9739FAQ38851516-C2B1BF21-ED70-428A-A196-9A2A70AD85D1Q39158845-560FDE52-0835-49AA-812F-246911159EA1Q41908976-495153EF-1462-45BD-A482-5BA7D1134FCCQ41937449-5E7CF76D-0B7A-44EC-9D2D-C6DA532D848AQ42014400-A55A24C3-4299-4620-9DD7-46BA072B49ACQ42117649-0A9D9E66-9B3E-4FA0-96B1-60AEE8EBC088Q42133338-7D7B3E15-97FA-41FD-980D-C1378EC4A2ACQ43001723-6A9D8CE5-2FAA-4C21-88D5-856E6E4C1F20Q51350882-F24A9331-AA72-477C-89F5-55D52178BCAAQ53045450-91DB834D-CCF0-451A-9206-E5EE8F048F3FQ55626892-85698D19-4889-4C94-BFED-99897C838266Q56969466-C7383F25-66BC-49D9-82A2-6AACCA9BEDDE
P2860
description
1960 nî lūn-bûn
@nan
1960年の論文
@ja
1960年論文
@yue
1960年論文
@zh-hant
1960年論文
@zh-hk
1960年論文
@zh-mo
1960年論文
@zh-tw
1960年论文
@wuu
1960年论文
@zh
1960年论文
@zh-cn
name
Peripheral neuritis due to isoniazid.
@en
Peripheral neuritis due to isoniazid.
@nl
type
label
Peripheral neuritis due to isoniazid.
@en
Peripheral neuritis due to isoniazid.
@nl
prefLabel
Peripheral neuritis due to isoniazid.
@en
Peripheral neuritis due to isoniazid.
@nl
P2093
P1476
Peripheral neuritis due to isoniazid
@en
P2093
ANDREWS RH
DEVADATTA S
GANGADHARAM PR
RAMAKRISHNAN CV
P304
P407
P577
1960-01-01T00:00:00Z